Interleukin-6 Signaling Effects on Ischemic Stroke and Other Cardiovascular Outcomes
2020; Wolters Kluwer; Volume: 13; Issue: 3 Linguagem: Inglês
10.1161/circgen.119.002872
ISSN2574-8300
AutoresMarios K. Georgakis, Rainer Malik, Dipender Gill, Nora Franceschini, Cathie Sudlow, Martin Dichgans, Sara Lindström, Lu Wang, Erin N. Smith, William Gordon, Astrid van Hylckama Vlieg, Mariza de Andrade, Jennifer A. Brody, Jack Pattee, Jeffrey Haessler, Ben Brumpton, Daniel I. Chasman, Pierre Suchon, Ming‐Huei Chen, Constance Turman, Marine Germain, Kerri L. Wiggins, James W. MacDonald, Sigrid K. Brækkan, Sebastian M. Armasu, Nathan Pankratz, R.D. Jackson, Jonas B. Nielsen, Franco Giulianini, Marja Puurunen, Manal Ibrahim, Susan R. Heckbert, Scott M. Damrauer, Pradeep Natarajan, Derek Klarin, Paul S. de Vries, Maria Sabater‐Lleal, Jennifer E. Huffman, Theo K. Bammler, Kelly A. Frazer, Bryan M. McCauley, Kent D. Taylor, James S. Pankow, Alexander P. Reiner, Maiken E. Gabrielsen, Jean‐François Deleuze, Chris O’Donnell, Jihye Kim, Barbara McKnight, Peter Kraft, JohnBjarne Hansen, Frits R. Rosendaal, John A. Heit, Bruce M. Psaty, Weihong Tang, Charles Kooperberg, Kristian Hveem, Paul M. Ridker, Pierre‐Emmanuel Morange, Andrew D. Johnson, Christopher Kabrhel, David‐Alexandre Trégouët, Nicholas L. Smith, Emelia Benjamin, Daniel I. Chasman, Abbas Dehghan, Tarunveer S. Ahluwalia, James B. Meigs, Russell Tracy, Behrooz Z. Alizadeh, Symen Ligthart, Josh Bis, Guðný Eiríksdóttir, Nathan Pankratz, Myron D. Gross, Alex Rainer, Harold Snieder, James Wilson, Bruce M. Psaty, Josée Dupuis, Bram P. Prins, Urmo Vaso, Maria G. Stathopoulou, Lude Franke, Terho Lehtimäki, Wolfgang Köenig, Yalda Jamshidi, Sophie Siest, Ali Abbasi, André G. Uitterlinden, Mohammadreza Abdollahi, Renate B. Schnabel, Ursula M. Schick, Ilja M. Nolte, Aldi T. Kraja, Yi‐Hsiang Hsu, Daniel S. Tylee, Alyson Zwicker, Rudolf Uher, George Davey Smith, Alanna C. Morrison, Andrew A. Hicks, Cornelia M. van Duijn, Cavin Ward‐Caviness, Eric Boerwinkle, Jerome I. Rotter, Kenneth Rice, Leslie A. Lange, Markus Perola, Eco J. C. de Geus, Andrew P. Morris, Kari Matti Makela, David Stacey, Johan G. Eriksson, Timothy M. Frayling, P. Eline Slagboom,
Tópico(s)Neuroinflammation and Neurodegeneration Mechanisms
ResumoHomeCirculation: Genomic and Precision MedicineVol. 13, No. 3Interleukin-6 Signaling Effects on Ischemic Stroke and Other Cardiovascular Outcomes Open AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyRedditDiggEmail Jump toOpen AccessLetterPDF/EPUBInterleukin-6 Signaling Effects on Ischemic Stroke and Other Cardiovascular OutcomesA Mendelian Randomization Study Marios K. Georgakis, MD, PhD, Rainer Malik, PhD, Dipender Gill, BMBCh, PhD, Nora Franceschini, MD, MPH, Cathie L. M. Sudlow, DPhil and Martin Dichgans, MD Marios K. GeorgakisMarios K. Georgakis https://orcid.org/0000-0003-3507-3659 Institute for Stroke and Dementia Research (ISD) (M.K.G., R.M., M.D.), University Hospital, Ludwig-Maximilians-University LMU, Munich, Germany. Graduate School for Systemic Neurosciences (GSN) (M.K.G.), University Hospital, Ludwig-Maximilians-University LMU, Munich, Germany. Search for more papers by this author , Rainer MalikRainer Malik Institute for Stroke and Dementia Research (ISD) (M.K.G., R.M., M.D.), University Hospital, Ludwig-Maximilians-University LMU, Munich, Germany. Search for more papers by this author , Dipender GillDipender Gill https://orcid.org/0000-0001-7312-7078 Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, United Kingdom (D.G., C.L.M.S.). Search for more papers by this author , Nora FranceschiniNora Franceschini https://orcid.org/0000-0001-9755-2175 Department of Epidemiology, UNC Gillings Global School of Public Health, Chapel Hill, NC (N.F.). Search for more papers by this author , Cathie L. M. SudlowCathie L. M. Sudlow Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, United Kingdom (D.G., C.L.M.S.). Institute for Genetics and Molecular Medicine, University of Edinburgh, United Kingdom (C.L.M.S.). Search for more papers by this author and Martin DichgansMartin Dichgans Correspondence to: Martin Dichgans, MD, Institute for Stroke and Dementia Research, University Hospital of Ludwig-Maximilians-University (LMU), Feodor-Lynen-Str. 17, 81377 Munich, Germany. Email E-mail Address: [email protected] https://orcid.org/0000-0002-0654-387X Institute for Stroke and Dementia Research (ISD) (M.K.G., R.M., M.D.), University Hospital, Ludwig-Maximilians-University LMU, Munich, Germany. Munich Cluster for Systems Neurology (SyNergy), Germany (M.D.). German Centre for Neurodegenerative Diseases (DZNE), Munich, Germany (M.D.). Search for more papers by this author and INVENT Consortiumand CHARGE Inflammation Working Group Originally published12 May 2020https://doi.org/10.1161/CIRCGEN.119.002872Circulation: Genomic and Precision Medicine. 2020;13:e002872Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: May 13, 2020: Ahead of Print Downregulation of IL-6 (interleukin-6) signaling has been proposed as a strategy for lowering cardiovascular risk. Secondary analyses from CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) demonstrated that the therapeutic benefit of IL-1β (interleukin-1β) inhibition on cardiovascular prevention was associated with the reduction of IL-6 levels and that the residual cardiovascular risk was proportional to post-treatment IL-6 levels.1 Moreover, Mendelian randomization (MR) analyses showed variation in IL-6R (IL-6 receptor) gene (IL6R) to be associated with risk of coronary artery disease.2 Thus, directly interfering with IL-6 signaling might lower cardiovascular risk beyond IL-1β inhibition. Whether such an approach would be effective for ischemic stroke and other cardiovascular outcomes (aortic aneurysm, carotid plaque, peripheral artery disease, atrial fibrillation, heart failure, and thrombotic phenotypes) remains unknown.Here, we identified genetic proxies for IL-6R-mediated downregulation of IL-6 signaling as variants within a region 300 kB 5′ to 300 kB 3′ to IL6R that were associated with lower CRP (C-reactive protein) levels. CRP is a well-established downstream molecule of IL-6 signaling and a clinically useful biomarker for assessing residual inflammatory cardiovascular risk. Variants were derived from a genome-wide association study of 204 402 European individuals (P<5×10−8; clumped at r2<0.1). We identified 7 single- nucleotide polymorphisms (SNPs) that served as instruments for downregulated IL-6 signaling (3 situated within IL6R). In conditional Genome-wide Complex Trait Analysis - conditional and joint (GCTA-CoJo) analyses3 adjusting for the lead SNP (rs2228145), P values for all SNPs were <0.05 (for SNPs within IL6R<0.0083-Bonferroni-corrected threshold) indicating independent effects on CRP levels. F statistics ranged from 81 to 764. To validate these instruments, we explored associations of genetically downregulated IL-6 signaling with circulating upstream regulators (IL-6, soluble IL-6R) and downstream molecules (fibrinogen) of the IL-6 signaling pathway. In accordance with trials testing tocilizumab versus placebo,2 genetically downregulated IL-6 signaling was associated with higher circulating IL-6 and soluble IL-6R levels and lower fibrinogen levels (Figure [A]).Download figureDownload PowerPointFigure. Genetic proxies for downregulated IL-6 (interleukin-6) signaling and their effects on ischemic stroke and other cardiovascular outcomes in Mendelian randomization analyses (MR).A, Effects of pharmacological inhibition of IL-6R (tocilizumab 8 mg/kg versus placebo for 8–24 weeks) and of genetic downregulation of IL-6 signaling on IL-6 (Ntrials=1446 and Ngenetics=8293), sIL-6R (soluble IL-6 receptor; Ntrials=1465 and Ngenetics=3301), and fibrinogen (Fg) levels (Ntrials=1108 and Ngenetics=120 246). B, Genetically downregulated IL-6 signaling in association with ischemic stroke and coronary artery disease as derived from inverse-variance weighted (IVW) analyses using the full set of 7 single-nucleotide polymorphisms (SNPs) as instruments or the 3 SNPs located within the IL6R gene. C, SNP-specific effects of the associations with ischemic stroke. D, Genetically downregulated IL-6 signaling and ischemic stroke subtypes. E, Distributions of the effects of 7 randomly selected CRP (C-reactive protein)-decreasing SNPs on risk of ischemic stroke and the position of the effect of the IL-6 signaling downregulating SNPs included in our analyses. F, Genetically downregulated IL-6 signaling with other cardiovascular outcomes. Effect sizes for genetically downregulated IL-6 signaling are scaled to the CRP-decreasing effects of tocilizumab (8 mg/kg). Statistical significance thresholds are set at P<0.05/3=0.017 for the 3 ischemic stroke subtypes, and at P<0.05/9=0.0055 for the 9 cardiovascular outcomes. Associations showing P values <0.05 are considered suggestive. SMD indicates standardized mean difference.Two-sample inverse-variance weighted MR analyses showed genetically downregulated IL-6 signaling to be associated with lower risks of ischemic stroke (MEGASTROKE: 34 217 cases and 404 630 controls) and coronary artery disease (Coronary Artery Disease Genome-wide Replication and Meta-analysis plus Coronary Artery Disease Genetics [CARDIoGRAMplusC4D]: 60 801 cases and 123 504 controls; Figure [B and C]). We further found associations with lower risks of large artery and small vessel stroke, but not cardioembolic stroke (Figure [D]). Alternative MR approaches (weighted median, contamination-mixture, MR-PRESSO) and sensitivity analyses restricted to the variants within IL6R all showed consistent association estimates.MR analyses revealed no significant associations between genetically determined CRP and ischemic stroke or its subtypes independently of whether we used all variants associated with CRP (187 SNPs) or SNPs at the CRP locus (24 SNPs). Furthermore, in permutations of MR analyses4 randomly selecting 7 of the 187 SNPs associated with CRP, the effects of the 7 SNPs selected as instruments for downregulated IL-6 signaling on ischemic stroke and its subtypes were consistently located below the lowest fifth percentile of the respective distributions (Figure [E]). Thus, the observed effects were independent of the effects of CRP.Finally, we expanded the analyses to other cardiovascular outcomes in the UK Biobank (321 406 individuals) and phenotype-specific genome-wide association study data sets. Genetically downregulated IL-6 signaling was significantly associated with lower risks of myocardial infarction and aortic aneurysm. We further found suggestive associations (P<0.05) with atrial fibrillation and carotid plaque (Figure [F]). Again, these associations were independent of CRP levels.Our results strongly support the candidacy of IL-6 signaling as a target for vascular prevention over and beyond previous data. CANTOS targeted IL-1β rather than IL-6R thus providing only indirect evidence for a benefit of interfering with IL-6 signaling.1 Also, CANTOS explored a combined end point rather than individual cardiovascular outcomes. Regarding stroke, there was a 7% reduction in incident events in the IL-1β arm, which did not reach statistical significance, and data on stroke subtypes were not available.5 Our MR results provide evidence for directionally consistent effects of IL-6 signaling on ischemic stroke and other cardiovascular outcomes and offer a solid basis for future trials exploring the benefit of pharmacological IL-6R inhibition for these phenotypes.Our results are in broad agreement with a recent MR study using the same data sources but a different approach to explore the effects of IL-6 signaling on cardiovascular outcomes.6 While that study used plasma levels of soluble IL-6R to proxy the effects of IL-6 signaling, we used CRP levels, which might explain some discrepancies in the results. We did not select variants based on their effects on IL-6 or soluble IL-6R because they are upstream regulators of IL-6 signaling and variants increasing their levels could also upregulate the pathway. Still, IL-6 signaling is complex with a classical and a trans-signaling component and disentangling the 2 subpathways goes beyond the limitations of MR.In conclusion, this study provides evidence for a causal effect of IL-6 signaling on ischemic stroke, particularly large artery and small vessel stroke, as well as a range of cardiovascular phenotypes. IL-6R blockade might represent a valid therapeutic target for lowering cardiovascular risk and should thus be further investigated in clinical trials.All data related to the effects of these variants on specific outcomes are publicly available as summary statistics from the respective sources. Data for outcomes derived from the UK Biobank are available after submission of a research proposal. All the data are also available from the corresponding author upon reasonable request. All individual studies had obtained ethical approval by the appropriate institutional review committees, as described in the original publications.AppendixINVENT Consortium membersSara Lindstrom, Lu Wang, Erin N. Smith, William Gordon, Astrid van Hylckama Vlieg, Mariza de Andrade, Jennifer A. Brody, Jack W. Pattee, Jeffrey Haessler, Ben M. Brumpton, Daniel I. Chasman, Pierre Suchon, Ming-Huei Chen, Constance Turman, Marine Germain, Kerri L. Wiggins, James MacDonald, Sigrid K. Braekkan, Sebastian M. Armasu, Nathan Pankratz, Rabecca D. Jackson, Jonas B. Nielsen, Franco Giulianini, Marja K. Puurunen, Manal Ibrahim, Susan R. Heckbert, Scott M. Damrauer, Pradeep Natarajan, Derek Klarin, Paul S. de Vries, Maria SabaterLleal, Jennifer E. Huffman, Theo K. Bammler, Kelly A. Frazer, Bryan M. McCauley, Kent Taylor, James S. Pankow, Alexander P. Reiner, Maiken E. Gabrielsen, Jean-François Deleuze, Chris J. O’Donnell, Jihye Kim, Barbara McKnight, Peter Kraft, JohnBjarne Hansen, Frits R. Rosendaal, John A. Heit, Bruce M. Psaty, Weihong Tang, Charles Kooperberg, Kristian Hveem, Paul M. Ridker, Pierre Emmanuel Morange, Andrew D. Johnson, Christopher Kabrhel, David-Alexandre Trégouët, Nicholas L. Smith.CHARGE Inflammation Working GroupEmelia Benjamin, Daniel I. Chasman, Abbas Dehghan, Tarunveer Singh Ahluwalia, James Meigs, Russell Tracy, Behrooz Z. Alizadeh, Symen Ligthart, Josh Bis, Gudny Eiriksdottir, Nathan Pankratz, Myron Gross, Alex Rainer, Harold Snieder, James G. Wilson, Bruce M. Psaty, Josee Dupuis, Bram Prins, Urmo Vaso, Maria Stathopoulou, Lude Franke, Terho Lehtimaki, Wolfgang Koenig, Yalda Jamshidi, Sophie Siest, Ali Abbasi, Andre G. Uitterlinden, Mohammadreza Abdollahi, Renate Schnabel, Ursula M. Schick, Ilja M. Nolte, Aldi Kraja, Yi-Hsiang Hsu, Daniel S. Tylee, Alyson Zwicker, Rudolf Uher, George Davey-Smith, Alanna C. Morrison, Andrew Hicks, Cornelia M. van Duijn, Cavin Ward-Caviness, Eric Boerwinkle, J. Rotter, Ken Rice, Leslie Lange, Markus Perola, Eco de Geus, Andrew P. Morris, Kari Matti Makela, David Stacey, Johan Eriksson, Tim M. Frayling, Eline P. Slagboom.Nonstandard Abbreviations and AcronymsCRPC-reactive proteinIL-1βinterleukin-1βIL-6Interleukin-6IL-6RInterleukin-6 receptorMRMendelian randomizationSNPsingle-nucleotide polymorphismAcknowledgmentsWe thank the following consortia for making data publicly available: MEGASTROKE Consortium, CARDIoGRAMplusC4D Consortium, CHARGE Consortium (Coronary Artery Disease Genome-wide Replication and Meta-analysis (CARDIOGRAM) plus the Coronary Artery Disease (C4D) Genetics), AFGen Consortium (Atrial Fibrillation Genetics), the YFS/FINRISK studies (Young Finnish Study/Finland Cardiovascular Risk), and the INTERVAL study. This research has been conducted using the UK Biobank Resource (UK Biobank application 2532, UK Biobank stroke study: developing an in-depth understanding of the determinants of stroke and its subtypes).Sources of FundingDr Georgakis was funded by scholarships from the Onassis Foundation and the German Academic Exchange Service (DAAD). Dr Gill is supported by the Wellcome Trust 4i Programme (203928/Z/16/Z) and British Heart Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College London. This project has received funding from the European Union’s Horizon 2020 research and innovation programme (No 666881), [email protected] (to Dr Dichgans) and No 667375, CoSTREAM (to Dr Dichgans); the DFG as part of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy: ID 390857198) and the CRC 1123 (B3) (to Dr Dichgans); the Corona Foundation (to Dr Dichgans); the Fondation Leducq (Transatlantic Network of Excellence on Pathogenesis of Small Vessel Disease of the Brain, to Dr Dichgans); the e:Med program (e:AtheroSysMed, to Dr Dichgans) and the FP7/2007-2103 European Union project [email protected] (grant agreement number Health-F2-2013-601456, to Dr Dichgans).DisclosuresNone.Footnotes*A list of all INVENT Consortium and CHARGE Inflammation Working Group participants is given in the AppendixFor Sources of Funding and Disclosures, see page 169.Correspondence to: Martin Dichgans, MD, Institute for Stroke and Dementia Research, University Hospital of Ludwig-Maximilians-University (LMU), Feodor-Lynen-Str. 17, 81377 Munich, Germany. Email martin.[email protected]uni-muenchen.deReferences1. Ridker PM, MacFadyen JG, Thuren T, Libby P. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1beta inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.Eur Heart J. 2019; pii:ehz542. doi: 10.1093/eurheartj/ehz542CrossrefGoogle Scholar2. Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JE, Shah T, Sofat R, Guo Y, Chung C, Peasey A, Pfister R, et al.; Interleukin-6 Receptor Mendelian Randomisation Analysis Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.Lancet. 2012; 379:1214–1224. doi: 10.1016/S0140-6736(12)60110-XCrossrefMedlineGoogle Scholar3. Yang J, Ferreira T, Morris AP, Medland SE, Madden PA, Heath AC, Martin NG, Montgomery GW, Weedon MN, Loos RJ, et al.; Genetic Investigation of ANthropometric Traits (GIANT) Consortium; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits.Nat Genet. 2012; 44:369–75, S1. doi: 10.1038/ng.2213CrossrefMedlineGoogle Scholar4. Gill D, Georgakis MK, Koskeridis F, Jiang L, Feng Q, Wei WQ, Theodoratou E, Elliott P, Denny JC, Malik R, et al.. Use of genetic variants related to antihypertensive drugs to inform on efficacy and side effects.Circulation. 2019; 140:270–279. doi: 10.1161/CIRCULATIONAHA.118.038814LinkGoogle Scholar5. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al.; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease.N Engl J Med. 2017; 377:1119–1131. doi: 10.1056/NEJMoa1707914CrossrefMedlineGoogle Scholar6. Rosa M, Chignon A, Li Z, Boulanger MC, Arsenault BJ, Bossé Y, Thériault S, Mathieu P. A Mendelian randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevity.NPJ Genom Med. 2019; 4:23. doi: 10.1038/s41525-019-0097-4CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited ByGeorgakis M, Malik R, Burgess S and Dichgans M (2021) Additive Effects of Genetic Interleukin‐6 Signaling Downregulation and Low‐Density Lipoprotein Cholesterol Lowering on Cardiovascular Disease: A 2×2 Factorial Mendelian Randomization Analysis, Journal of the American Heart Association, 11:1, Online publication date: 4-Jan-2022. Rahman R, McEwan L, Ryan D and Gill D (2021) Leveraging genetic data to investigate the effects of interleukin‐6 receptor signalling on levels of 40 circulating cytokines, British Journal of Clinical Pharmacology, 10.1111/bcp.15079, 88:3, (1373-1378), Online publication date: 1-Mar-2022. Cupido A, Asselbergs F, Natarajan P, Ridker P, Hovingh G and Schmidt A (2022) Dissecting the IL‐6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R , British Journal of Clinical Pharmacology, 10.1111/bcp.15191, 88:6, (2875-2884), Online publication date: 1-Jun-2022. Feinstein M, Buzkova P, Olson N, Doyle M, Sitlani C, Fohner A, Huber S, Floyd J, Sinha A, Thorp E, Landay A, Freiberg M, Longstreth W, Tracy R, Psaty B and Delaney J (2022) Monocyte subsets, T cell activation profiles, and stroke in men and women: The Multi-Ethnic Study of Atherosclerosis and Cardiovascular Health Study, Atherosclerosis, 10.1016/j.atherosclerosis.2022.05.007, 351, (18-25), Online publication date: 1-Jun-2022. Liberale L, Badimon L, Montecucco F, Lüscher T, Libby P and Camici G (2022) Inflammation, Aging, and Cardiovascular Disease, Journal of the American College of Cardiology, 10.1016/j.jacc.2021.12.017, 79:8, (837-847), Online publication date: 1-Mar-2022. Georgakis M, Parodi L, Frerich S, Mayerhofer E, Tsivgoulis G, Pirruccello J, Slowik A, Rundek T, Malik R, Dichgans M, Rosand J and Anderson C (2022) Genetic Architecture of Stroke of Undetermined Source: Overlap with Known Stroke Etiologies and Associations with Modifiable Risk Factors, Annals of Neurology, 10.1002/ana.26332, 91:5, (640-651), Online publication date: 1-May-2022. Perry B, Bowker N, Burgess S, Wareham N, Upthegrove R, Jones P, Langenberg C and Khandaker G (2022) Evidence for Shared Genetic Aetiology Between Schizophrenia, Cardiometabolic, and Inflammation-Related Traits: Genetic Correlation and Colocalization Analyses, Schizophrenia Bulletin Open, 10.1093/schizbullopen/sgac001, 3:1, Online publication date: 1-Jan-2022. Papadopoulos A, Palaiopanos K, Björkbacka H, Peters A, de Lemos J, Seshadri S, Dichgans M and Georgakis M (2021) Circulating Interleukin-6 Levels and Incident Ischemic Stroke, Neurology, 10.1212/WNL.0000000000013274, 98:10, (e1002-e1012), Online publication date: 8-Mar-2022. Kamtchum-Tatuene J, Saba L, Heldner M, Poorthuis M, de Borst G, Rundek T, Kakkos S, Chaturvedi S, Topakian R, Polak J and Jickling G (2022) Interleukin-6 Predicts Carotid Plaque Severity, Vulnerability, and Progression, Circulation Research, 131:2, (e22-e33), Online publication date: 8-Jul-2022.Georgakis M, Malik R, Li X, Gill D, Levin M, Vy H, Judy R, Ritchie M, Verma S, Nadkarni G, Damrauer S, Theodoratou E and Dichgans M (2021) Genetically Downregulated Interleukin-6 Signaling Is Associated With a Favorable Cardiometabolic Profile, Circulation, 143:11, (1177-1180), Online publication date: 16-Mar-2021.Georgakis M and Gill D (2021) Mendelian Randomization Studies in Stroke: Exploration of Risk Factors and Drug Targets With Human Genetic Data, Stroke, 52:9, (2992-3003), Online publication date: 1-Sep-2021.Zuber V, Cameron A, Myserlis E, Bottolo L, Fernandez‐Cadenas I, Burgess S, Anderson C, Dawson J and Gill D (2021) Leveraging Genetic Data to Elucidate the Relationship Between COVID‐19 and Ischemic Stroke, Journal of the American Heart Association, 10:22, Online publication date: 16-Nov-2021. Tonomura S and Gyanwali B (2021) Cerebral microbleeds in vascular dementia from clinical aspects to host-microbial interaction, Neurochemistry International, 10.1016/j.neuint.2021.105073, 148, (105073), Online publication date: 1-Sep-2021. Ye Z, Kappelmann N, Moser S, Davey Smith G, Burgess S, Jones P and Khandaker G (2021) Role of inflammation in depression and anxiety: Tests for disorder specificity, linearity and potential causality of association in the UK Biobank, EClinicalMedicine, 10.1016/j.eclinm.2021.100992, 38, (100992), Online publication date: 1-Aug-2021. Kappelmann N, Arloth J, Georgakis M, Czamara D, Rost N, Ligthart S, Khandaker G and Binder E (2021) Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms, JAMA Psychiatry, 10.1001/jamapsychiatry.2020.3436, 78:2, (161), Online publication date: 1-Feb-2021. Kappelmann N, Dantzer R and Khandaker G (2021) Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19, Psychoneuroendocrinology, 10.1016/j.psyneuen.2021.105295, 131, (105295), Online publication date: 1-Sep-2021. Ryan D, Karhunen V, Walker D and Gill D (2021) Inhibition of interleukin 6 signalling and renal function: A Mendelian randomization study, British Journal of Clinical Pharmacology, 10.1111/bcp.14725, 87:7, (3000-3013), Online publication date: 1-Jul-2021. Larsson S, Burgess S and Gill D (2020) Genetically proxied interleukin-6 receptor inhibition: opposing associations with COVID-19 and pneumonia, European Respiratory Journal, 10.1183/13993003.03545-2020, 57:1, (2003545), Online publication date: 1-Jan-2021. Levin M, Klarin D, Assimes T, Freiberg M, Ingelsson E, Lynch J, Natarajan P, O’Donnell C, Rader D, Tsao P, Chang K, Voight B and Damrauer S (2021) Genetics of Smoking and Risk of Atherosclerotic Cardiovascular Diseases, JAMA Network Open, 10.1001/jamanetworkopen.2020.34461, 4:1, (e2034461) Jenkins R, Hughes S, Figueras A and Jones S (2021) Unravelling the broader complexity of IL-6 involvement in health and disease, Cytokine, 10.1016/j.cyto.2021.155684, 148, (155684), Online publication date: 1-Dec-2021. Sordillo P and Sordillo L (2021) Glioblastoma cell-induced immunosuppression causing chemoresistance Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies, 10.1016/B978-0-12-821567-8.00008-7, (293-317), . Ziegler L, Wallén H, Aspberg S, de Faire U and Gigante B (2021) IL6 trans-signaling associates with ischemic stroke but not with atrial fibrillation, BMC Neurology, 10.1186/s12883-021-02321-6, 21:1, Online publication date: 1-Dec-2021. Perry B, Upthegrove R, Kappelmann N, Jones P, Burgess S and Khandaker G (2021) Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian randomization study, Brain, Behavior, and Immunity, 10.1016/j.bbi.2021.07.009, 97, (176-185), Online publication date: 1-Oct-2021. Bovijn J, Lindgren C and Holmes M (2020) Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19, The Lancet Rheumatology, 10.1016/S2665-9913(20)30345-3, 2:11, (e658-e659), Online publication date: 1-Nov-2020. Kao T and Huang C (2022) Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases, International Journal of Molecular Sciences, 10.3390/ijms23020804, 23:2, (804) Barh D, Aljabali A, Tambuwala M, Tiwari S, Serrano-Aroca Á, Alzahrani K, Silva Andrade B, Azevedo V, Ganguly N and Lundstrom K (2021) Predicting COVID-19—Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management, Biomedicines, 10.3390/biomedicines9050556, 9:5, (556) Poznyak A, Bharadwaj D, Prasad G, Grechko A, Sazonova M and Orekhov A (2021) Anti-Inflammatory Therapy for Atherosclerosis: Focusing on Cytokines, International Journal of Molecular Sciences, 10.3390/ijms22137061, 22:13, (7061) Nasonov E (2021) Coronavirus disease 2019 (COVID-19) and autoimmunity, Rheumatology Science and Practice, 10.47360/1995-4484-2021-5-30, 59:1, (5-30) Hong J, Qu Z, Ji X, Li C, Zhang G, Jin C, Wang J, Zhang Y, Shen Y, Meng J, Zhou C, Fang C, Wang W and Yan S (2021) Genetic Associations Between IL-6 and the Development of Autoimmune Arthritis Are Gender-Specific, Frontiers in Immunology, 10.3389/fimmu.2021.707617, 12 Acosta J, Szejko N and Falcone G (2021) Mendelian Randomization in Stroke: A Powerful Approach to Causal Inference and Drug Target Validation, Frontiers in Genetics, 10.3389/fgene.2021.683082, 12 Gallego-Fabrega C, Muiño E, Cárcel-Márquez J, Llucià-Carol L, Lledós M, Martín-Campos J, Cullell N and Fernández-Cadenas I (2022) Genome-Wide Studies in Ischaemic Stroke: Are Genetics Only Useful for Finding Genes?, International Journal of Molecular Sciences, 10.3390/ijms23126840, 23:12, (6840) Da Silva-Candal A, Dopico-López A, Pérez-Mato M, Rodríguez-Yáñez M, Pumar J, Ávila-Gómez P, Castillo J, Sobrino T, Campos F, Hervella P and Iglesias-Rey R (2021) Characterization of a Temporal Profile of Biomarkers as an Index for Ischemic Stroke Onset Definition, Journal of Clinical Medicine, 10.3390/jcm10143136, 10:14, (3136) Niu P, Wang X and Xu Y (2021) Association of Interleukin-6 Signaling and C-Reactive Protein With Intracranial Aneurysm: A Mendelian Randomization and Genetic Correlation Study, Frontiers in Genetics, 10.3389/fgene.2021.679363, 12 Vandebergh M, Becelaere S, Dubois B and Goris A (2022) Body Mass Index, Interleukin-6 Signaling and Multiple Sclerosis: A Mendelian Randomization Study, Frontiers in Immunology, 10.3389/fimmu.2022.834644, 13 June 2020Vol 13, Issue 3Article InformationMetrics © 2020 The Authors. Circulation: Genomic and Precision Medicine is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.https://doi.org/10.1161/CIRCGEN.119.002872PMID: 32397738 Originally publishedMay 12, 2020 Keywordscoronary artery diseasecardiovascular diseasesgeneticsstrokeinflammationPDF download Advertisement SubjectsCardiovascular DiseaseCerebrovascular Disease/StrokeEpidemiologyGeneticsInflammation
Referência(s)